Analyst firms · UBS · BRKR
UBS BRKR price target and rating history
Bruker Corporation (BRKR) · Health Care
UBS rates Bruker Corporation (BRKR) Neutral with a $65 price target, as of its latest action on Sep 9, 2026. It has published 3 rating actions on BRKR since October 2022, including 0 upgrades and 0 downgrades. Across 4 firms with a BRKR price target in the last 12 months, the median target is $60. UBS's $65 is 8% above that.
- Current rating
- Neutral
- Price target
- $65
- Median target, all firms
- $60
- Actions on BRKR
- 3
UBS price target on BRKR
Every UBS rating on BRKR
- Sep 9, 2026
- Dec 10, 2024
- Oct 21, 2022
How other firms rate BRKR
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| UBS | Neutral | $65 | Sep 9, 2026 |
| Wolfe Research | Peer Perform | $60 | Jun 2, 2026 |
| Goldman Sachs | Sell | $40 | Dec 9, 2025 |
| Rothschild & Co Redburn | Buy | $60 | Nov 20, 2025 |
Questions about UBS and BRKR
- What is UBS's price target for BRKR?
- UBS's latest stated price target for Bruker Corporation (BRKR) is $65, from its action on Sep 9, 2026.
- What is UBS's rating on BRKR?
- UBS rates BRKR Neutral, a neutral rating, as of Sep 9, 2026.
- When did UBS last change its view on BRKR?
- On Sep 9, 2026, UBS starts coverage at Neutral, price target $65.
- How does UBS's BRKR target compare with other analysts?
- Across 4 firms with a BRKR price target in the last 12 months, the median target is $60. UBS's $65 is 8% above that.
More BRKR rating histories
All UBS ratingsBRKR news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.